Seattle, WA and Sunnyvale,
CA, - October 28, 2007
Calypso® Medical and IMPAC Medical Systems, an Elekta company,
have identified product collaboration projects which will
further enable integration of oncology management systems with
the Calypso 4D Localization System. Designed to provide an
objective and continuous method to setup patients for radiation
treatment, the Calypso 4D Localization System monitors the
patient during treatment without adding ionizing radiation.
“Calypso plans to work with IMPAC to provide our customers with
innovative approaches to real-time organ motion management from
patient setup through treatment,” says Eric R. Meier, President
and CEO of Calypso Medical. “We anticipate workflow gains that
will further solidify our platform as ideal and unique, as well
as, continuous and real-time target localization solution.”
Precise setup, consistent delivery, and accurate treatment
documentation are critical to radiation oncology. With this
product collaboration, customers will be able to more
efficiently manage target motion with the addition of new
features such as the capability of remote table repositioning.
Accurate and precise delivery of radiation treatment will be
ensured by correcting for motion detected by the Calypso System
prior to and during the actual treatment.
"IMPAC is looking forward to working closely with Calypso to
optimize our customers clinical workflow in managing the
challenges associated with organ motion,” says Jay Hoey,
Executive Vice President Product Creation at Elekta and CEO of
IMPAC Medical Systems. The real-time motion data generated by
the Calypso System introduces new and exciting options which
will advance adaptive radiation therapy approaches, as well as
provide data management solutions for our mutual customers.”
About Calypso Medical
Calypso Medical Technologies, Inc. (“Calypso”) is a Seattle,
WA based privately held medical device company. The company’s
proprietary tumor localization system utilizes miniaturized
implanted devices (Beacon® electromagnetic transponders) to
continuously, accurately, and objectively pinpoint the location
of tumors for improved accuracy in radiation therapy. Calypso
addresses two major issues in modern radiation oncology: errors
in treatment set-up and tumor motion during treatment. In
addition, the Calypso 4D Localization System’s non-ionizing
electromagnetic guidance has the potential to improve work flow
efficiency and treatment room utilization. The technology is
designed for body-wide cancers commonly treated with radiation
therapy, including prostate, breast, lung, head, neck and other
radiation therapy target organs. The products are FDA 510(k)
cleared for use in the prostate. More information can be found
at www.calypsomedical.com.
About Elekta and IMPAC
Elekta Inc., IMPAC Medical Systems, Medical Intelligence and 3D
Line Medical Systems are all part of the Elekta Group, an
international medical technology corporation, providing
meaningful solutions, comprehensive information systems and
services for improved cancer care and management of brain
disorders.
All of Elekta’s solutions employ non-invasive or minimally
invasive techniques and are therefore clinically effective,
gentle on the patient and cost-effective. Elekta is listed on
the Nordic Exchange under the ticker EKTAb and the company head
office is located in Stockholm, Sweden. For additional
information, please visit www.elekta.com and www.impac.com. |
|
Media Inquiries:
Michelle Lee
PR and Advertising Manager
Tel: +1 770-670-2447
michelle.lee@elekta.com
Global Marketing inquiries: Peter Gaccione
Vice President,
Global Marketing
Tel: +1 770-670-2380
peter.gaccione@elekta.com
Investor inquiries:
Peter Ejemyr
Group VP,
Corporate Communications, Tel: +46 733 611 000
peter.ejemyr@elekta.com
Calypso Medical
Media Inquiries:
Lynn Purdy
Tel: +1 206 774-4213
lpurdy@calypsomedical.com
Link Disclaimer
|
